OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Official title

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Study identification

NCT ID

NCT07136012

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Amgen

Industry

Enrollment

11,000 participants

Conditions and interventions

Eligibility (public fields only)

Age range

50 Years to 105 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Aug 21, 2025

Primary completion

Oct 19, 2031

Completion

Oct 19, 2031

Last update posted

Apr 23, 2026

2025 – 2031

United States locations

U.S. sites

200

U.S. states

37

U.S. cities

171

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.